The association between nm23-H1 expression and survival in patients with esophageal squamous cell carcinoma

Cancer Letters

Volumn 138, Issue 1-2, 1999, Pages 139-144

  Iizuka, Norio ^a   Tangoku, Akira ^a   Hayashi, Hiroto ^a   Yosino, Shigehumi ^a   Abe, Toshihiro ^a   Morioka, Takayuki ^a   Oka, Masaaki ^a  

^a YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Esophageal cancer; Metastasis; NM23; Prognosis

Indexed keywords

CISPLATIN;

ARTICLE; CLINICAL ARTICLE; ESOPHAGUS CARCINOMA; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; METASTASIS POTENTIAL; PRIORITY JOURNAL; PROGNOSIS; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MONOMERIC GTP-BINDING PROTEINS; NUCLEOSIDE-DIPHOSPHATE KINASE; PROGNOSIS; SURVIVAL RATE; TRANSCRIPTION FACTORS;

EID: 0033606087     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(98)00387-5     Document Type: Article

References (22)

1. Roder J.D., Busch R., Stein H.J., Fink U., Siewert J.R. Ratio of invaded to removed lymph nodes as a predictor of survival in squamous cell carcinoma of the oesphagus. Br. J. Surg. 81:1994;410-413.
2. Steeg P.S., Bevilacqua G., Kopper L., Thorgeirsson U.P., Talmadge J.B., Liotta L.A., Sobel M. Evidence for a novel gene associated with low tumor metastatic potential. J. Natl. Cancer Inst. 80:1988;200-204.
3. Florenes V.A., Aamdal S., Myklebost O., Maelandsmo G., Bruland O.S., Fodstad O. Levels of nm23 messenger RNA in metastatic malignant melanomas: inverse correlation to disease progression. Cancer Res. 52:1992;6088-6091.
4. Tokunaga Y., Urano T., Furukawa K., Kondo H., Kanematsu T., Shiku H. Reduced expression of nm23-H1, but not of nm23-H2 is concordant with the frequency of lymph node metastasis of human breast cancer. Int. J. Cancer. 55:1993;66-71.
5. Iizuka N., Oka M., Noma T., Nakazawa A., Hirose K., Suzuki T. NM23-H1 and NM23 H2 messenger RNA abundance in human hepatocellular carcinoma. Cancer Res. 55:1995;652-657.
6. Lindmark G. NM-23 H1 immunohistochemistry is not useful as predictor of metastatic potential of colorectal cancer. Br. J. Cancer. 74:1996;1413-1418.
7. Higashiyama M., Doi O., Yokouchi H., Kodama K., Nakamori S., Tateishi R., Kimura N. Immunohistochemical analysis of nm23 gene product/NDP kinase expression in pulmonary adenocarcinoma: Lack of prognostic value. Br. J. Cancer. 66:1992;533-536.
8. Wang C.S., Lin K.H., Hsu Y.C., Hsueh S. Distant metastasis of gastric cancer is associated with elevated expression of the antimetastatic nm23 gene. Cancer Lett. 128:1998;23-29.
9. Patel D.D., Bhatavdekar J.M., Chikhlikar P.R., Patel Y.V., Shah N.G., Ghosh N., Suthar T.P., Balbar D.B. Clinical significance of pS3, nm23, and bc1-2 in T3-4N IMO oesophageal carcinoma: an immunohistochemical approach. J. Surg. Oncol. 65:1997;111-116.
10. Holm R., Tanum G. Evaluation of the prognostic significance of nm23/NDP kinase and cathepsin D in anal carcinomas. An immunohistochemical study. Virchows Arch. 428:1996;85-89.
11. Gazzeri S., Brambilla E., Negoescu A., Thoraval D., Veron M., Moro D., Brambilla C. Overexpression of nucleoside diphosphate/kinase A/nm23-H1 protein in human lung tumors: association with tumor progression in squamous carcinoma. Lab. Invest. 74:1996;158-167.
12. Sobin L.H., Wittekind C. UICC International Union Against Cancer. TNM Classification of Malignant Tumors. 5th edn. 1997;Wiley-Liss. pp. 54-58.
13. Cox D.R. Regression models and life table. J. R. Stat. Soc. 34:1972;187-220.
14. Kaplan B.L., Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53:1958;457-481.
15. Mandai M., Konishi I., Koshiyama M., Komatsu T., Yamamoto S., Nanbu K., Mori T., Fukumoto M. Altered expression of nm23-H1 and e-erbB-2 proteins have prognostic significance in adenocarcinoma but not in squamous cell carcinoma of the uterine cervix. Cancer. 75:1995;2523-2529.
16. Nakayama H., Yasui W., Yokozaki H., Tahara E. Reduced expression of nm23 is associated with metastasis of human gastric carcinomas. Jpn. J. Cancer Res. 84:1993;184-190.
17. Konishi N., Nakaoka S., Tsuzuki T., Matsumoto K., Kitahori Y., Hiasa Y., Urano T., Shiku H. Expression of nm23-H1 and nm23-H2 proteins in prostate carcinoma. Jpn. J. Cancer Res. 84:1993;1050-1054.
18. Nakayama T., Ohtsuru A., Nakao K., Shima M., Nakata K., Watanabe K., Ishli N., Kimura N., Nagataki S. Expression in human hepatocellular carcinoma of nucleoside diphosphate kinase, a homologue of the nm23 gene product. J. Natl. Cancer Inst. 84:1992;1349-1354.
19. Aklyama H., Tsurumaru M., Udagawa H., Kajiyama Y. Radical lymph node dissection for cancer of the thoracic esophagus. Ann. Surg. 220:1994;364-372.
20. Ferguson A.W., Flatow U., MacDonald N.J., Larminat F., Bohr V.A., Steeg P.S. Increased sensitivity to cisplatin by nm23-transfected tumor cell lines. Cancer Res. 56:1996;2931-2935.
21. Freije J.M., Lawrence J.A., Hollingshead M.G., De la Rosa A., Narayanan Y., Grever M., Sausville E.A., Paull K., Steeg P.S. Identification of compounds with preferential inhibitory activity against low-Nm23-expressing human breast carcinoma and melanoma cell lines. Nature Med. 4:1997;395-401.
22. Scambia G., Ferrandina G., Marone M., Benedetti P.P., Giannitelli C., Piantelli M., Leone A., Mancuso S. Nm23 in ovarian cancer: correlation with clinical outcome and other clinicopathologic and biochemical prognostic parameters. J. Clin. Oncol. 14:1996;334-342.